UTEBZI Drug Patent Profile
When do Utebzi patents expire, and what generic alternatives are available?
Utebzi is a drug marketed by Glaxosmithkline and is included in one NDA. There are two patents protecting this drug.
The generic ingredient in UTEBZI is tebipenem pivoxil hydrobromide. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the tebipenem pivoxil hydrobromide profile page.
DrugPatentWatch® Generic Entry Outlook for Utebzi
Utebzi will be eligible for patent challenges on June 17, 2030. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be June 17, 2036. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for UTEBZI?
- What are the global sales for UTEBZI?
- What is Average Wholesale Price for UTEBZI?
Summary for UTEBZI
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| DailyMed Link: | UTEBZI at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for UTEBZI
Generic Entry Date for UTEBZI*:
Constraining patent/regulatory exclusivity:
GENERATING ANTIBIOTIC INCENTIVES NOW NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for UTEBZI
UTEBZI is protected by two US patents and two FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of UTEBZI is ⤷ Start Trial.
This potential generic entry date is based on GENERATING ANTIBIOTIC INCENTIVES NOW.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline | UTEBZI | tebipenem pivoxil hydrobromide | TABLET;ORAL | 215960-001 | Jun 17, 2026 | RX | Yes | Yes | 12,226,403 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Glaxosmithkline | UTEBZI | tebipenem pivoxil hydrobromide | TABLET;ORAL | 215960-001 | Jun 17, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Glaxosmithkline | UTEBZI | tebipenem pivoxil hydrobromide | TABLET;ORAL | 215960-001 | Jun 17, 2026 | RX | Yes | Yes | 10,889,587 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Glaxosmithkline | UTEBZI | tebipenem pivoxil hydrobromide | TABLET;ORAL | 215960-001 | Jun 17, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for UTEBZI
See the table below for patents covering UTEBZI around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2018215687 | ⤷ Start Trial | |
| Australia | 2020281120 | ⤷ Start Trial | |
| Brazil | 112019015487 | ⤷ Start Trial | |
| Canada | 3049690 | ⤷ Start Trial | |
| China | 110234651 | ⤷ Start Trial | |
| China | 117551102 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |

